Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Blood Cancer. 2009 Feb;52(2):259-62. doi: 10.1002/pbc.21757.

One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.

Author information

1
Texas Children's Cancer Center and Hematology Service, Baylor College of Medicine, Houston, Texas, USA.

Abstract

BACKGROUND:

We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm(3) within the first 12 weeks. These patients were followed for the next year.

METHODS:

Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted.

RESULTS:

Eight of the 11 initial responders maintained a platelet count over 150,000/mm(3) without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm(3) without the need for further intervention.

CONCLUSIONS:

Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm(3) or higher in 11 of 36 patients (31%).

PMID:
18937333
DOI:
10.1002/pbc.21757
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center